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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.021Background: Hypothermic depolarizing hyperkalemic (K 20 mEq/L) blood car-
dioplegia is the “gold standard” in cardiac surgery. K has been associated with
deleterious consequences, eg, intracellular calcium overload. This study tested the
hypothesis that elective arrest in a polarized state with adenosine (400 mol/L via
adenosine triphosphate–sensitive potassium channel opening) and the Na channel
blocker lidocaine (750 mol/L) as the arresting agents in blood cardioplegia
provides cardioprotection comparable to standard hypothermic K-blood cardio-
plegia.
Methods: Anesthetized dogs were placed on cardiopulmonary bypass and as-
signed to 1 of 3 groups receiving antegrade cardioplegia delivered every 20
minutes for 1 hour of arrest: cold (10°C) K-blood cardioplegia (n  6), cold
(10°C) adenosine/lidocaine blood cardioplegia (n  6), or warm (37°C) aden-
osine/lidocaine blood cardioplegia (n  6). After an hour of arrest, cardiopul-
monary bypass was discontinued, and reperfusion was continued for 120 min-
utes.
Results: Time to arrest was longer with cold and warm adenosine/lidocaine blood
cardioplegia (175  19 seconds and 143  19 seconds, respectively) compared
with K-blood cardioplegia (27  2 seconds; P  .001). Postcardioplegia left
ventricular systolic function (slope of the end-systolic pressure/dimension rela-
tionship) was comparable among the 3 groups (K-blood cardioplegia, 15.2 
2.1 mm Hg/mm; cold adenosine/lidocaine blood cardioplegia, 15.9  3.4 mm
Hg/mm; warm adenosine/lidocaine blood cardioplegia, 14.1  2.8 mm Hg/mm;
P  .90). Plasma creatine kinase activity in cold and warm adenosine/lidocaine
blood cardioplegia was similar to that in K-blood cardioplegia at 120 minutes
of reperfusion (cold adenosine/lidocaine blood cardioplegia, 11.5  2.1 IU/g
protein; warm adenosine/lidocaine blood cardioplegia, 10.1  0.9 IU/g protein;
K-blood cardioplegia, 7.6  0.8 IU/g protein; P  .17). Postcardioplegia
coronary artery endothelial function was preserved in all groups.
Conclusions: Intermittent polarized arrest with warm or cold adenosine/lidocaine
blood cardioplegia provided the same degree of myocardial protection as intermit-
tent hypothermic K-blood cardioplegia in normal hearts.
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CSPHyperkalemic cardioplegia is the “goldstandard” method to arrest the heart. Ahigh potassium concentration depolarizesthe myocyte membrane and induces elec-tromechanical arrest. Hypothermia is alsofrequently used for intermittent cardiople-
gia. However, there are disadvantages to using both depo-
larizing potassium cardioplegia and hypothermia, especially
in severely injured hearts. Membrane depolarization with
potassium is associated with continued ion exchange across
the cell membrane through sodium and calcium “window
currents,” intracellular sodium and calcium overload,1 con-
tinued energy expenditure, and cardiomyocyte dysfunction
and death.2 To counter the increased energy expenditure,
hypothermia effectively reduces oxygen demand but causes
membrane instability, edema, arrhythmias, and slows the
metabolic and functional recovery of the postischemic myo-
cyte.3,4
An alternative approach to arresting the heart is to main-
tain the transmembrane electrical potential in a polarized
state,5 which locks the ion channels in a “closed” state.
Therefore, ionic imbalances and subsequent consequences
are likely to be avoided.5 Adenosine triphosphate–sensitive
potassium channel opening (PCO) agents (eg, nicorandil
and aprikalim) have been used to achieve polarized or
hyperpolarized arrest.6,7 However, PCO agents have been
reported to increase postischemic arrhythmias8 and myocar-
dial oxygen demand on reperfusion and to produce pro-
found systemic hypotension. For these reasons, hyperpolar-
ized arrest with PCO agents as the arresting agent has not
been adopted as a clinical cardioplegia strategy.
The combination of adenosine and lidocaine is an alter-
native method to achieve polarized arrest.9 Adenosine acti-
vates adenosine triphosphate–sensitive potassium channels
by A1-receptor–mediated mechanisms.10,11 Lidocaine, a
widely used local anesthetic, prevents transmembrane de-
polarization and electrical activation by blocking sodium
channels. The combination of lidocaine and adenosine in-
duces polarized arrest in either a normothermic or hypo-
thermic environment9,12 and may therefore offer an alterna-
tive method of inducing cardioplegia. This study tested the
hypothesis that polarized arrest with normothermic or hy-
pothermic adenosine/lidocaine blood cardioplegia (AL-
BCP) provides similar cardioprotection to the gold standard
hypothermic depolarizing hyperkalemic blood cardioplegia
(K-BCP) in normal myocardium when used in a canine
model of cardiopulmonary bypass (CPB).
Materials and Methods
All animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press (revised
1996). Dogs were premedicated with morphine sulfate (4 mg/kg
600 The Journal of Thoracic and Cardiovascular Surgery ● Marintramuscularly). General anesthesia was induced with sodium
pentothal (20 mg/kg intravenously [IV]) and maintained by con-
tinuous infusion of fentanyl (0.4 g · kg1 · min1) and diazepam
(3 g · kg1 · min1). Nembutal injections (20-30 mg/kg IV) were
administered as needed for supplemental anesthesia. Dogs were
endotracheally intubated and mechanically ventilated (Ohmeda
ventilator, BOC Group Inc, Madison, Wis) to maintain a pH of
7.35 to 7.45, a PO2 of greater than 100 mm Hg, and a PCO2 of 35
to 45 mm Hg. A polyethylene catheter was inserted into the right
femoral artery to monitor systemic arterial pressure and to sample
arterial blood.
The chest was opened via median sternotomy. The pericardium
was incised and sutured to form a cradle. Millar MPC-500 (Millar
Instruments, Inc, Houston, Tex) solid-state pressure catheters were
placed into the left ventricle (LV) via an apical incision and into
the aortic arch via the right internal thoracic artery to continuously
measure the LV and aortic pressures, respectively. A pair of
2-mm-diameter 10-MHz piezoelectric ultrasonic crystals (Sono-
metrics Corporation, London, Ontario, Canada) were placed in the
subendocardium in the anterior/posterior minor axis of the LV to
measure global systolic and diastolic characteristics by pressure-
dimension loop analysis.
Heparin (300 mg/kg IV) was given and supplemented (150
mg/kg IV) every 90 minutes thereafter. The left subclavian artery
was cannulated (20F; Baxter Healthcare Corporation, Midvale,
TABLE 1. Blood cardioplegia volumes and myocardial tem-
peratures
Variable Volume (mL) Ant T (°C) Post T (°C)
BCP1
Warm AL-BCP 1084 70 34.6 0.5 35.1  0.4
Cold AL-BCP 643 31* 18.3 0.8* 15.9  0.7*
K-BCP 595 85* 18.4 1.2* 15.9  1.0*
BCP2
Warm AL-BCP 379 26 32.6 0.5 33.9  0.4
Cold AL-BCP 274 32 18.8 0.4* 17.4  0.5*
K-BCP 480 76*† 16.5 1.2*† 14.1 1.1*†
BCP3
Warm AL-BCP 387 21 33.1 0.5 34.3  0.4
Cold AL-BCP 284 29 19.4 0.5* 18.0  0.8*
K-BCP 500 79*† 16.3 0.8*† 15.2 0.8*†
BCP4 (hot shot)
Warm AL-BCP 1246 45 35.2 0.2 35.8 0.1
Cold AL-BCP 1104 64 33.8 0.4 33.7 1.3
K-BCP 934 85* 33.1 0.7* 35.0  0.3
Total BCP volume
Warm AL-BCP 3096 163
Cold AL-BCP 2305 156
K-BCP 2508 325
AL, Adenosine/lidocaine; BCP, blood cardioplegia; BCP1, induction BCP
infusion; BCP2 and BCP3, Intermittent CP infusions; BCP4, terminal BCP
infusion; Ant T, myocardial temperature in the anterior left ventricle; Post
T, myocardial temperature in the posterior left ventricle.
*P  .05 versus warm AL-BCP.
†P  .05 versus cold AL-BCP.Utah) for systemic perfusion, and the right atrium was cannulated
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Pwith a 2-stage cannula (36/46F; United States Surgical Corpora-
tion, Norwalk, Conn) to harvest venous return. A double-lumen
DLP cardioplegia cannula (Medtronic, Inc, Minneapolis, Minn)
was inserted in the proximal ascending aorta for delivery of BCP,
and the LV was vented (20F; United States Surgical Corporation).
CPB was initiated with a membrane oxygenator (Cobe Cardio-
vascular, Inc, Arvada, Colo). Mean arterial blood pressure during
CPB was maintained at 70 mm Hg by adjusting the arterial flow
rate. The dogs were randomly divided into 3 groups. In the
K-BCP group (n  6), multidose hyperkalemic BCP (8 parts
blood to 1 part crystalloid) was delivered with the Myocardial
Protection System (Quest Medical, Inc, Allen, Tex). The crystal-
loid component contained tromethamine (THAM) 823 mmol/L,
sodium 103 mEq/L, citrate 57.5 mEq/L, phosphate 92.5 mEq/L,
and dextrose 233 mmol/L. K-BCP was delivered with the cold
induction modality (3-minute induction infusion at 10°C; 20
mEq/L K final concentration), with subsequent infusions made at
20 and 40 minutes at 10°C for 2 minutes each (10 mEq/L K). The
terminal delivery was a modifed “hot shot” (20 mEq/L K).13
In the cold AL-BCP group (n 6), hypothermic BCP (22 parts
blood to 1 part crystalloid, ie, minicardioplegia,14 with 400
mol/L adenosine and 750 mol/L lidocaine per liter of cardio-
plegia without other additives) was delivered by the Myocardial
Protection System. Adenosine was delivered via a separate line to
avoid degradation by adenosine deaminase. Cold AL-BCP was
delivered using the cold induction strategy as in the K-BCP
group. The duration of induction was the greater of 2 minutes or
the time necessary to achieve arrest plus an additional 30 seconds.
Intermittent infusions of 1 minute each were made at 20 and 40
TABLE 2. Hemodynamic and cardiodynamic characteristic
Variable HR (beats/min)
LV max
(mm Hg)
LV E
(mm
Baseline
Warm AL-BCP 102.1 4.5 98.3  4.5 10.0
Cold AL-BCP 96.7 6.7 103.7 3.2 5.8 
K-BCP 102.1 4.8 105.3 3.9 7.3 
R60
Warm AL-BCP 145.1 3.3† 91.2 5.5† 8.5
Cold AL-BCP 129.2 8.2† 96.2 1.7 5.2
K-BCP 141.9 3.5† 93.2 4.0† 6.9
R90
Warm AL-BCP 143.7 6.1† 88.7 3.3† 8.0
Cold AL-BCP 119.6 7.1*† 95.6 3.7 5.9
K-BCP 137.2 5.9† 91.9 2.5† 6.5
R120
Warm AL-BCP 134.8 5.6† 88.3 2.8† 8.3
Cold AL-BCP 119.3 8.5† 98.5 2.5 5.8
K-BCP 134.0 4.9† 89.7 3.4† 6.5
HR, Heart rate; LV max, maximal left ventricular pressure; LV EDP, left ven
of left ventricular pressure; Ao mean, aortic mean pressure; ESD, end-systo
minor axis dimension; R60, 60 minutes of reperfusion; R90, 90 minutes of rep
cardioplegia.
*P  .05 versus warm AL-BCP,
†P  .05 versus baseline within each group by repeated-measures analyminutes. After 60 minutes of arrest, a terminal hot shot was
The Journal of Thoracidelivered for 3 minutes with adenosine but without lidocaine to
reduce the overall dose of lidocaine. In the warm AL-BCP group
(n  6), multidose normothermic BCP (22:1) with 400 mol/L
adenosine and 750 mol/L lidocaine was administered at 37°C in
the same manner as cold AL-BCP. All cardioplegia solutions were
infused at a pressure of 50 mm Hg. The total time of elective arrest
was 60 minutes.
Immediately after completion of the terminal cardioplegia de-
livery, systemic blood pressure was adjusted to 50 mm Hg, and the
aortic crossclamp was removed. After electromechanical reanima-
tion, the perfusion pressure was increased to 80 mm Hg over 3 to
5 minutes. The heart was reperfused on CPB for 30 minutes, after
which reperfusion was continued on CPB for 2 hours.
The animals were euthanized with sodium pentobarbital (100
mg/kg IV) at the end of the experiment. The heart was immediately
excised and placed into 4°C Krebs-Henseleit buffer (118 mmol/L
NaCl, 4.7 mmol/L KCl, 1.2 mmol/L KH2PO4, 1.2 mmol/L MgSO4,
2.5 mmol/L CaCl2, 12.5 mmol/L NaHCO3, and 10 mmol/L glucose at
pH 7.4).
Data Acquisition and Analysis
Analog cardiodynamic and hemodynamic data were digitized and
recorded on a personal computer by using SonoView Cardiovas-
cular Acquisition software (Sonometrics Corporation). Data were
acquired at baseline (after instrumentation and a brief period of
stabilization and before the initiation of CPB) and at 60, 90, and
120 minutes after removal of the aortic crossclamp. Data analysis
was performed with SPECTRUM cardiovascular data analysis
dP/dt max
Ao mean
(mm Hg) ESD (mm) EDD (mm)
1065 51 86.3  3.7 30.7 2.6 35.5  2.5
1202 90 86.5  4.2 33.6 1.4 39.6  1.5*
1124 66 90.8  3.5 31.2 2.9 37.3  1.9
955 43† 75.8 5.9† 33.2 2.1 36.0  2.2
1024 68† 76.2 3.2† 35.2 1.4 39.8  1.5
968 80† 76.4 4.6† 32.4 2.8 36.1  2.2
925 43† 74.8 3.6† 33.2 2.2 36.3  2.3
927 46 75.4 3.5 35.7 1.4 40.1  1.4
906 51† 74.4 3.2† 32.4 2.8 35.8  2.4
854 45† 75.3 2.8† 33.6 2.2 36.6  2.3
916 55† 80.1 2.2 36.5 1.1 40.7  1.3
833 44† 73.5 4.4† 32.4 2.9 35.7  2.5
ar end-diastolic pressure; dP/dt max, maximal value of the first derivative
terior/posterior minor axis dimension; EDD, end-diastolic anterior/posterior
ion; R120, 120 minutes of reperfusion; AL, adenosine lidocaine; BCP, blood
variance.s
DP
Hg)
1.4
0.9*
0.7
2.0
0.8
0.8
1.6
0.6
0.8
1.4
0.9
0.8
tricul
lic an
erfussoftware (Wake Forest University, Winston-Salem, NC).
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Global systolic and diastolic function. Global systolic
function was quantified by end-systolic pressure/minor axis
dimension relations (ESPDR) and preload-recruitable stroke
work (PRSW) as previously described.15 Global diastolic func-
tion was quantified by fitting the declining end-diastolic pres-
sure/diameter points obtained during inferior vena cava occlu-
sion to an exponential curve and calculating the degree of
curvature (-coefficient).
Plasma creatine kinase activity. Arterial plasma creatine ki-
nase (CK) levels were taken at baseline, 5 minutes after the
institution of CPB, after each BCP delivery, and at 60, 90, and
120 minutes of reperfusion off CPB, and were assayed
spectrophotometrically.13
Myocardial tissue water content. Tissue water content was
determined by 72-hour dessication of transmural LV myocardial
Figure 1. End-systolic pressure/dimension relationship
end-systolic pressure/dimension relationship during tr
contractility. R60, R90, and R120, 60, 90, and 120 minut
Figure 2. Left ventricular preload recruitable stroke wo
minor axis diameter data. PRSW, Preload recruitable
reperfusion, respectively.biopsy samples taken at the conclusion of the experiment. The
602 The Journal of Thoracic and Cardiovascular Surgery ● Marpercentage of tissue water content was also determined in normal
hearts (n  6) not subjected to CPB, for reference.
Myeloperoxidase activity in myocardium. Myeloperoxidase,
an enzyme relatively specific for neutrophils, was determined in
the postexperimental myocardium by using a modification of the
method of Mullane and colleagues16 and was reported as the rate
of hydrogen peroxide degradation–induced color change in absor-
bance units per minute per gram of tissue.
Postexperimental coronary artery endothelial function. The
postexperimental left anterior descending coronary artery was iso-
lated from the excised heart to determine vascular endothelial
function in organ chambers by using relaxation responses of pre-
constricted (U46619; 5 mol/L) arterial segments to incremental
concentrations of endothelium-dependent (acetylcholine, A23187)
and -independent (sodium nitroprusside) vasodilators, as described
previously. Indomethacin (10 mol/L) was added to the buffer to
aseline and during reperfusion. ESPDR, Slope of the
nt caval occlusion, an index of global left ventricular
reperfusion, respectively.
uring baseline and reperfusion, derived from pressure/
e work; R60, R90, and R120, 60, 90, and 120 minutes ofat b
ansierk d
strokinhibit endogenous prostanoids.
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All data are reported as mean  SEM. A 1-way analysis of
variance (ANOVA) and ANOVA for repeated measures were used
to compare single-point and time-dependent variables in multiple
groups, respectively, followed by a post hoc Student-Neuman-
Keuls test correcting for multiple comparisons to indentify the
source of significant differences.
Results
The induction volume of K-BCP and cold AL-BCP was
significantly less than that in the warm AL-BCP group (P
.05; Table 1). Intermittent infusion volumes of BCP were
significantly greater in cold K-BCP than in the warm
AL-BCP and cold AL-BCP groups because the infusion
time for the K-BCP group was 2 minutes, versus 1 minute
Figure 3. Left ventricular end-diastolic pressure/dime
stiffness. , Modulus of diastolic stiffness obtained by
during transient caval occlusion to a curve, an inverse
90, and 120 minutes of reperfusion, respectively. †P <
Figure 4. Plasma creatine kinase activity during the
initiation of CPB; BCP1, sampled at the end of the indu
intermittent BCP infusions; BCP4, sampled at the end o
90, and 120 minutes of reperfusion, respectively. *P <for the AL-BCP groups. However, there was no significant
The Journal of Thoracidifference among groups in total cardioplegia volumes. The
steady-state hemodynamic profiles of the 3 groups were
similar during the course of the experiment (Table 2), with
the exception that heart rate was significantly higher in
warm AL-BCP versus cold AL-BCP (P  .045) at 120
minutes of reperfusion.
There was no difference between the AL-BCP groups in
the duration of the induction infusion (cold, 205  21
seconds; warm, 189  14 seconds) versus the prescribed
180 seconds in the K-BCP group. However, the time to
mechanical arrest was significantly longer in both the cold
AL-BCP and the warm AL-BCP groups (175  19 seconds
and 143  19 seconds, respectively) versus the K-BCP
group (27  2 seconds; P  .001). Complete electrome-
chanical arrest was not achieved within the 2-minute time
relationship as a measure of global left ventricular
ng successive end-diastolic pressure points obtained
of left ventricular compliance; R60, R90, and R120, 60,
ersus baseline values by repeated-measures ANOVA.
se of the experiment. CPB, Sampled 5 minutes after
BCP infusion; BCP2 and BCP3, sampled at the end of
inal BCP infusion; R60, R90, and R120, sampled at 60,
for cold AL-BCP versus K-BCP at R60.nsion
fitti
indexcour
ction
f termframe in 2 of 6 animals in the cold AL-BCP group. Fur-
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CSPthermore, breakthrough reanimation was present in 5 of 6
hearts receiving cold AL-BCP.
Ventricular fibrillation during early reperfusion was ob-
served in 1 experiment in each of the cold AL-BCP and
warm AL-BCP groups. During the terminal hot shot infu-
sion in which lidocaine was omitted, hearts in the warm and
cold AL-BCP groups began to reanimate 86  15 seconds
and 74  9 seconds into infusion, respectively, whereas
hearts in the K-BCP group remained arrested for the
duration of the terminal cardioplegia. Hearts in the K-BCP
group reanimated 140  15 seconds after removal of the
crossclamp, and this was significantly longer than the time
to reanimation in the AL-BCP groups during terminal car-
dioplegia.
The slope of the ESPDR was comparable at baseline in all
groups (Figure 1). There was no significant change in the slope
of the ESPDR from baseline during any time in reperfusion,
and there were no significant group differences at any time
during reperfusion. In addition, there was no difference in the
PRSW at any time point (Figure 2). The -coefficient of the
end-diastolic pressure/dimension relation was comparable be-
tween groups at baseline. Reperfusion was associated with a
significant increase in diastolic stiffness compared to baseline
in all groups (P  .05 by repeated-measures ANOVA; Figure
3); however, there were no significant group differences
throughout reperfusion.
Plasma CK activity was similar in all groups at baseline and
during arrest (BCP1–BCP4 in Figure 4). Plasma CK activity
was significantly greater in the cold AL-BCP group versus
K-BCP at 60 minutes of reperfusion (P  .002). However,
there was no statistically significant difference in CK activity
Figure 5. Postexperimental left anterior descending (LAD) coro-
nary artery endothelial and smooth muscle function. Maximal
relaxation responses to acetylcholine (ACh), calcium ionophore
A23187 (A23), and sodium nitroprusside (SNP) are shown in pos-
texperimentally excised epicardial LAD coronary arteries. Max-
imum values were determined from stepwise incremental con-
centrations of each drug.among groups at 120 minutes of reperfusion (P  .17).
604 The Journal of Thoracic and Cardiovascular Surgery ● MarPostexperimental myocardial tissue water content was
comparable among all groups (K-BCP, 78.4%  0.4%;
warm AL-BCP, 78.6%  0.2%; cold AL-BCP, 77.7% 
0.2%), and there was no significant difference from that in
normal hearts (n  6) not subjected to cardioplegic arrest
and CPB (77.9%  0.3%; P  .15).
Myeloperoxidase activity was comparable between
warm AL-BCP (10.0  1.1 absorbance units/min/g) and
K-BCP (7.4  1.1 absorbance units/min/g; P  .24).
However, myeloperoxidase activity was significantly
greater in cold AL-BCP (20.3  2.1 absorbance units/
min/g) when compared with both warm AL-BCP and K-
BCP (P  .001 for both comparisons).
Postexperimental left anterior descending coronary ar-
tery endothelial function, quantified by the maximum endo-
thelial-dependent vasorelaxation responses at the highest
concentrations of acetylcholine (690 nmol/L) and endothe-
lium-dependent receptor-independent calcium ionophore
A23187 (380 nmol/L) used, was comparable among groups
(Figure 5). Coronary vascular smooth muscle relaxation
determined by the maximal response to sodium nitroprus-
side (190 nmol/L; Figure 5) was similarly comparable
among groups. Therefore, postcardioplegia coronary vascu-
lar reactivity as a measure of endothelial function was
comparably preserved in all groups.
Discussion
This study compared depolarized arrest using potassium
against polarized arrest using the unique combination of
adenosine and lidocaine in blood cardioplegia under hypo-
thermia and normothermia. The time to complete arrest was
prolonged with both hypothermic and normothermic AL-
BCP compared to potassium cardioplegia. However, post-
cardioplegia systolic function, diastolic stiffness, and over-
all global performance (PRSW) in hearts receiving either
cold or warm AL-BCP were comparable to hypothermic
K-BCP. Neutrophil accumulation in myocardium was
comparable in the warm AL-BCP and hypothermic K-
BCP groups but was greater in the cold AL-BCP group. In
addition, plasma CK release and coronary artery endothelial
function were comparable among all groups. Therefore,
postcardioplegia functional outcomes achieved with nonde-
polarizing AL-BCP were comparable to those of the stan-
dard cold K-BCP. Furthermore, nondepolarizing arrest
with intermittent AL-BCP can be used at normothermic
temperatures, thereby avoiding the need for either profound
hypothermia or continuous delivery of warm depolarizing
K-BCP formulations.
Hypothermia has been considered a cornerstone of myo-
cardial protection. However, hypothermia has also been
associated with deleterious changes in the myocardium.
Contractile dysfunction,17 uncoupling of excitation-contrac-
tion mechanisms, edema, and calcium dyshomeostasis18
ch 2005
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Phave been noted after rewarming from profound hypother-
mia. Recovery of LV systolic and diastolic performance has
been shown to be decreased or delayed after arrest with cold
cardioplegia19 compared with warm cardioplegia. Cold car-
dioplegia has been associated with more frequent perioper-
ative infarctions and postoperative low-output syndrome.20
In this study, we did not observe any untoward effects of
hypothermia in these normal canine ventricles compared
with their normothermic AL-BCP counterparts. Future stud-
ies should compare the postcardioplegia function of isch-
emically injured ventricles to determine whether warm AL-
BCP can avoid the disadvantages of hypothermia.
Warm cardioplegia avoids the membrane instability and
reduces the ion dyshomeostasis that is associated with hy-
pothermia4 and has been advocated for better myocardial
protection over cold cardioplegia.21 However, warm cardio-
plegia must be administered continuously or nearly contin-
uously to avoid ischemia. The results from this study sug-
gest that normothermia can be safely used even with
intermittent delivery of cardioplegia solution when the heart
is arrested in a polarized state by using adenosine and
lidocaine as arresting agents. The study by Dobson and
Jones9 suggests that the metabolic rate is dramatically re-
duced during polarized arrest with adenosine and lidocaine.
The observation that postcardioplegia outcomes are compa-
rable between the warm AL-BCP and cold K-BCP groups
is consistent with this notion.
The delay in arrest with AL-BCP contrasts with the rapid
arrest observed with crystalloid AL-BCP reported by Dob-
son and Jones9 in an isolated perfused rat heart preparation.
The concentration of adenosine may have been suboptimal
for the canine myocardium. The concentration of adenosine
(400 mol/L) was limited by the high concentration of
adenosine needed in the crystalloid concentrate to achieve
target concentrations in 22:1 blood cardioplegia, and by the
maximum pump delivery configuration of the cardioplegia
delivery system. While the concentration of adenosine was
twofold higher than Dobson and Jones’ crystalloid cardio-
plegia (0.2 mmol/L),9 it was less than 5% of the maximum
concentrations employed by Schubert and colleagues22 (20
mmol/L) and Boehm and associates23 (10 mmol/L). The
intravascular concentration of adenosine may have been
rapidly reduced by adenosine deaminase in the interim
between infusions. In addition, the failure of hypothermic
AL-BCP to achieve complete quiescence may be related to
lidocaine’s sensitivity to temperature; lidocaine fails to
maintain the membrane potential at the resting value under
profound hypothermia (10°C).24 This temperature sensitiv-
ity is specific for lidocaine because the prototype Na
channel blocker tetrodotoxin does not show such tempera-
ture dependence.5 Therefore, lidocaine may be more effec-
tive at normothermic or tepid temperatures, which is con-
The Journal of Thoracisistent with the superior arrest achieved with normothermic
AL-BCP observed in this study.
Neutrophil accumulation was paradoxically greater in
the cold AL-BCP group, despite similar functional recovery
at the end of reperfusion. It is unlikely that the increased
neutrophil accumulation is representative of a proinflamma-
tory effect of adenosine mediated by A1-receptor activation,
because the counterbalancing anti-inflammatory effects me-
diated by A2-receptor activation are more potent. In any
event, the increased neutrophil accumulation in cold AL-
BCP did not adversely affect postcardioplegia contractile or
coronary artery endothelial function. This finding may sug-
gest that neutrophils do not play a major role in postisch-
emic contractile function, as has been reported in other
models of ischemic and reperfused myocardium.25
Lidocaine was removed from the terminal blood cardio-
plegia to reduce the total systemic lidocaine load and to
avoid potential lidocaine toxicity. The removal of lidocaine
was associated with reanimation of the heart, thus empha-
sizing the need for simultaneous delivery of both agents in
combination to achieve cardioplegia. However, reanimation
during infusion of terminal blood cardioplegia should not be
problematic because the oxygen requirements of the vented
heart are supported by delivery of blood. Accordingly,
reanimation of the myocardium during the terminal cardio-
plegia phase did not adversely affect ventricular or endo-
thelial function. Additionally, cardiac motion during the
terminal infusion is not likely to interrupt the surgical pro-
cedure, because only proximal anastomoses are being con-
structed or all anastomoses have already been completed if
performed under a single crossclamp. Whether resumption
of electromechanical activity during terminal cardioplegia is
tolerated in ischemically injured hearts in which cardiople-
gia plays a resuscitative role should be determined by fur-
ther experiments with appropriate models.
In conclusion, normothermic depolarized arrest with AL-
BCP may have advantages over hyperkalemic depolarizing
cardioplegia in protecting the heart during chemical arrest.
Future studies are warranted to elucidate the mechanisms of
protection with depolarized arrest versus the gold standard
potassium depolarized arrest in more challenging models of
cardiac surgery, such as surgical reperfusion of ischemically
injured myocardium, prolonged crossclamp times, or pro-
longed storage for transplantation. In addition, future stud-
ies on AL-BCP should quantify postcardioplegia arrhyth-
mias, because adenosine has potent inhibitory effects on
ventricular fibrillation26 mediated by an A1 receptor mech-
anism. Finally, future studies should optimize the dose of
adenosine in blood cardioplegia. The concentration used in
the present study was 20% of the highest dose (2 mmol/L)
reported by Mentzer and colleagues using adenosine in
hyperkalemic blood cardioplegia in humans27; hence,
c and Cardiovascular Surgery ● Volume 129, Number 3 605
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CSPhigher doses of adenosine than used in the present study
may facilitate more rapid arrest.
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